Zacks Investment Research upgraded shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) from a hold rating to a buy rating in a research report released on Friday, September 1st. Zacks Investment Research currently has $1.50 price target on the stock.
According to Zacks, “Ekso Bionics Holdings, Inc. is engaged in designing, developing and selling wearable robots or exoskeletons for the medical, military, industrial and consumer markets. The company’s operating segment consists of Engineering Services and Medical segments. It operates primarily in North America, Western Europe, the Middle East and South Africa. Ekso Bionics Holdings, Inc. is headquartered in Richmond, California. “
Separately, B. Riley reaffirmed a buy rating and issued a $4.00 price target on shares of Ekso Bionics Holdings in a research note on Wednesday, May 10th.
Ekso Bionics Holdings (EKSO) traded down 6.50% during trading on Friday, hitting $1.15. 613,937 shares of the stock were exchanged. The firm has a 50-day moving average of $1.47 and a 200-day moving average of $2.19. Ekso Bionics Holdings has a 52 week low of $0.99 and a 52 week high of $6.38. The stock’s market capitalization is $29.66 million.
COPYRIGHT VIOLATION WARNING: “Ekso Bionics Holdings, Inc. (EKSO) Raised to “Buy” at Zacks Investment Research” was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this piece on another publication, it was stolen and republished in violation of international copyright and trademark law. The original version of this piece can be viewed at https://ledgergazette.com/2017/09/16/zacks-investment-research-upgrades-ekso-bionics-holdings-inc-ekso-to-buy.html.
In related news, insider Russ Angold sold 28,254 shares of the company’s stock in a transaction on Wednesday, August 16th. The stock was sold at an average price of $1.53, for a total value of $43,228.62. Following the sale, the insider now directly owns 250,678 shares of the company’s stock, valued at $383,537.34. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Over the last ninety days, insiders purchased 41,264 shares of company stock worth $48,255 and sold 259,352 shares worth $399,373. 7.10% of the stock is owned by corporate insiders.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Intellectus Partners LLC grew its stake in shares of Ekso Bionics Holdings by 5.3% in the second quarter. Intellectus Partners LLC now owns 105,294 shares of the company’s stock worth $244,000 after acquiring an additional 5,294 shares during the last quarter. Independence Advisors LLC purchased a new stake in shares of Ekso Bionics Holdings in the second quarter worth $1,840,000. Carl Domino Inc grew its stake in shares of Ekso Bionics Holdings by 74.7% in the second quarter. Carl Domino Inc now owns 82,054 shares of the company’s stock worth $190,000 after acquiring an additional 35,088 shares during the last quarter. National Planning Corp grew its stake in shares of Ekso Bionics Holdings by 116.2% in the second quarter. National Planning Corp now owns 234,450 shares of the company’s stock worth $537,000 after acquiring an additional 126,000 shares during the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Ekso Bionics Holdings by 32.9% in the second quarter. Vanguard Group Inc. now owns 711,082 shares of the company’s stock worth $1,650,000 after acquiring an additional 176,197 shares during the last quarter. 6.04% of the stock is currently owned by hedge funds and other institutional investors.
About Ekso Bionics Holdings
Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ekso Bionics Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.